<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699943</url>
  </required_header>
  <id_info>
    <org_study_id>21511-01</org_study_id>
    <nct_id>NCT03699943</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.</brief_title>
  <official_title>Feasibility Study of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creative Medical Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creative Medical Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assessed the safety and efficacy of autologous bone marrow concentrate and&#xD;
      injected intra-cavernously into patients with erectile dysfunction (ED). Specifically, this&#xD;
      study will evaluate ED treatment &gt;18 year old men, a demographic where the etiology of ED is&#xD;
      attributable primarily to the loss of corporal smooth muscle in the penis. Study endpoints&#xD;
      will evaluate the safety and efficacy of intracavernosal bone marrow concentrate&#xD;
      administration for treating ED patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erectile dysfunction (ED) is characterized by abnormalities of the vascular system; most&#xD;
      commonly, venous leakage (or veno-occlusive dysfunction) resulting from loss of integrity of&#xD;
      the surrounding corporal smooth muscle. In the penile vascular system, the corporal smooth&#xD;
      muscle is responsible for trapping the blood delivered to the corpora cavernosa via the&#xD;
      arterial system.&#xD;
&#xD;
      Bone marrow is enriched for cells with regenerative potential, including mesenchymal stem&#xD;
      cells, which accelerate healing of damaged tissue. The possibility of using bone marrow cells&#xD;
      in the treatment of ED is enticing since stem/progenitor cell populations are known to&#xD;
      secrete various growth factors, possess anti-inflammatory activities, and can differentiate&#xD;
      into cells of the penile architecture.&#xD;
&#xD;
      This study will evaluate safety and efficacy of autologous bone marrow concentrate generated&#xD;
      by a closed system device and injected intra-cavernously in 40 patients aged &gt; 18 years of&#xD;
      age diagnosed with erectile dysfunction with low dose 30 cc (20 patients) or high dose 60 cc&#xD;
      (20 patients). Safety and efficacy will be evaluated at baseline (prior to treatment) and at&#xD;
      1,3,6 and 12-month follow up visits. The study will determine whether injection of bone&#xD;
      marrow cells intra-cavernously is a clinically feasible, safe and reproducible approach for&#xD;
      treating erectile dysfunction. A clinical registry will also be enrolling treating the same&#xD;
      patient population (100 patients (20 cc)).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2015</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Caverstem 1.0 - Low dose - 30 cc - 20 patients Caverstem 1.0 - High dose - 60 cc - 20 patients Caverstem 2.0 - 20 cc - 100 patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in erectile function as measured by total score in the International Index of Erectile Function</measure>
    <time_frame>6 months</time_frame>
    <description>IIEF-5 scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>bruising, infection, pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Doppler Measurements</measure>
    <time_frame>6 months</time_frame>
    <description>ml/s</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>CaverStem 1.0 - Low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CaverStem 1.0 - High</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caverstem 2.0 - Clinical Registry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CaverStem</intervention_name>
    <arm_group_label>CaverStem 1.0 - High</arm_group_label>
    <arm_group_label>CaverStem 1.0 - Low</arm_group_label>
    <arm_group_label>Caverstem 2.0 - Clinical Registry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic organic ED duration at least 0.5 years&#xD;
&#xD;
          2. Diagnosis of ED based on Doppler Ultrasound and/or dynamic infusion cavernosonometry.&#xD;
&#xD;
          3. Baseline International Index of Erectile Function (IIEF-5) score of &lt; 21&#xD;
&#xD;
          4. Oral medications and intracavernous pharmacological approaches have been deemed&#xD;
             ineffective, contraindicated or cannot be tolerated.&#xD;
&#xD;
          5. Concurrently undergoing treatment with testosterone.&#xD;
&#xD;
          6. Willing to forego any other treatments for ED over the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects using any medications/drugs with known effects on erectile function within 4&#xD;
             weeks of the study period, including certain antidepressants, antihistamines,&#xD;
             diuretics, and beta-blockers.&#xD;
&#xD;
          2. Subjects using herbal remedies for addressing erectile dysfunction within one month of&#xD;
             study initiation.&#xD;
&#xD;
          3. Subjects with penile prosthesis or other urinary prosthesis.&#xD;
&#xD;
          4. Subjects with penile anatomical deformities (e.g. Peyronie's disease) or history of&#xD;
             priapism.&#xD;
&#xD;
          5. Previous penile surgeries for erectile dysfunction, premature ejaculation or penile&#xD;
             enlargement.&#xD;
&#xD;
          6. Diagnosis of psychogenic ED as determined by nocturnal tumenscence testing.&#xD;
&#xD;
          7. Presenting with uncontrolled or severe disease, including cardiovascular disease,&#xD;
             diabetes, liver disease.&#xD;
&#xD;
          8. Uncontrolled hypertension or hypotension (systolic blood pressure &gt; 170 or &lt; 90 mm Hg,&#xD;
             and diastolic blood pressure &gt; 100 or &lt; 50 mm Hg)&#xD;
&#xD;
          9. Suffered a cardiovascular event within 6 months prior to study initiation.&#xD;
&#xD;
         10. Current or previous malignancy other than non-melanoma skin cancer (successfully&#xD;
             treated or treatable by curative excision or other local curative therapy).&#xD;
&#xD;
         11. Diagnosis of a systemic autoimmune disorder.&#xD;
&#xD;
         12. Receiving immunosuppressant medications.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Gershman</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA/Cedar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Rajfer</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor - UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared among other investigators through secure clinical registry.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

